Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. von Mehren, M; Arlen, P; Gulley, J; Rogatko, A; Cooper, HS; Meropol, NJ; Alpaugh, RK; Davey, M; McLaughlin, S; Beard, MT; Tsang, KY; Schlom, J; Weiner, LM
   The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
   CLINICAL CANCER RESEARCH
   
   M. von Mehren et al., "The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma", CLIN CANC R, 7(5), 2001, pp. 1181-1191
2. von Mehren, M; Arlen, P; Tsang, KY; Rogatko, A; Meropol, N; Cooper, HS; Davey, M; McLaughlin, S; Schlom, J; Weiner, LM
   Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
   CLINICAL CANCER RESEARCH
   
   M. von Mehren et al., "Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas", CLIN CANC R, 6(6), 2000, pp. 2219-2228
3. von Mehren, M; Weiner, LM
   Breast cancer: Biologic therapy
   STRATEGIES IN ADJUVANT THERAPY
   
   M. von Mehren e L.M. Weiner, "Breast cancer: Biologic therapy", STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 203-232
4. Alpaugh, K; von Mehren, M
   Monoclonal antibodies in cancer treatment - A review of recent progress
   BIODRUGS
   
   K. Alpaugh e M. von Mehren, "Monoclonal antibodies in cancer treatment - A review of recent progress", BIODRUGS, 12(3), 1999, pp. 209-236
5. Alpaugh, RK; von Mehren, M; Palazzo, I; Atkins, MB; Sparano, JA; Schuchter, L; Weiner, LM; Dutcher, JP
   Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
   MEDICAL ONCOLOGY
   
   R.K. Alpaugh et al., "Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon", MED ONCOL, 15(3), 1998, pp. 191-198